Conflicts with a french shareholder: how to escape a joint venture
Le 17 septembre 2014 Par Benoît LAFOURCADE
Generally, French joint ventures with a foreign shareholder are secured with deadlock resolution mechanisms.
A number of methods are considered in order to break deadlocks of varying degrees, including:
- Providing for a chairman to have a second vote;
- Mandating a period and process for parties to seek resolution;
- Escalating the issue to senior officers of the parties for resolution;
- Providing for exit options with pricing mechanisms.
Ideally, the foreign shareholder will be provided with a sale option or the possibility to purchase the shares of the other party (at an agreed price or one fixed by a third party arbitrator appointed by the court).
One potential provision is the so-called “Russian Roulette” clause. This clause involves one party offering to either buy or sell their shares to or from the other at a specified price. The one who receives the offer then has the option to accept the offer or alternatively to require the initiating party to buy or sell its own shares on the same terms.
There may also be a provision allowing a party to sell to a third party subject with the consent of the remaining party of the joint venture. If the incoming partner has the same skills set as the departing shareholder, this can often provide a good solution for all parties concerned.
In the absence of specific provisions in a company’s bye-laws or a shareholders’ agreement, are any solutions available according to French law in the event of an unresolved dispute between shareholders resulting in a deadlock?
A radical option would be to file a petition for liquidation.
This is possible under French law in very limited circumstances, notably if the company is no more in a position to do business.
Another option is to consider selling the shareholding interest in the joint venture to the other shareholders. However, if contractual mechanisms have not been agreed upfront, it will be impossible to force the other shareholder to buy the shares.
Consequently, a though negotiation will start. Exit options would probably result in a sale at a discount or symbolic price.
Alternatively, the shareholder will try to identify efficient levies for the negotiation. In one case scenario, majority shareholders may have committed a fault in the management (if member of a management committee) or when voting at shareholders’ meeting (minority shareholders may bring actions against majority shareholders who abuse their rights and cause a prejudice to the company or other shareholders).
If the joint venture is controlled by foreign shareholders (holding sufficient majority at the shareholder’s meeting), the shareholders can still consider a few restructuring options (e.i. sale of the business to a newcomer, decrease of capital followed by an increase if the accounting situation allows it) to dilute the other shareholders or even evict them. Such options have to be carefully studied before being implemented as it may generate liabilities.
Nos derniers articles
Coordination des systèmes de retraite : quel cadre juridique pour les carrières internationales ?
La mobilité internationale des travailleurs implique une articulation complexe entre plusieurs systèmes nationaux de sécurité sociale. En matière de retraite, cette situation soulève des enjeux juridiques majeurs : quelle législation s’applique à un salarié détaché ou expatrié ? Comment ses droits acquis sont-ils conservés d’un pays à l’autre ? Selon quelles modalités sa pension sera-t-elle […]
Lire l'article
Pénalité de 40 % pour manquement délibéré : quand l’incertitude juridique fait obstacle à la majoration
Dans une décision du 12 mars 2026, le Conseil d’État rappelle un principe fondamental du contentieux fiscal : une difficulté réelle d’interprétation de la loi peut suffire à écarter la majoration de 40 % pour manquement délibéré, y compris lorsque le contribuable est assisté d’un professionnel. Une décision utile à intégrer dans toute stratégie de […]
Lire l'article
DELCADE accompagne Geistlich Pharma AG dans la prise de contrôle d’OST Développement
Le marché européen de la médecine régénérative poursuit sa consolidation. Le 24 avril 2026, le groupe suisse Geistlich Pharma AG a finalisé l’acquisition d’une participation majoritaire dans OST Développement, spécialiste français de la régénération osseuse. DELCADE est intervenu en qualité de conseil juridique de l’acquéreur, prolongeant ainsi une collaboration entamée dès 2024. Une opération M&A […]
Lire l'article